Kyverna Therapeutics, Inc.
KYTXNasdaq
$7.45
↑ +0.1%Jul 17 close · end-of-day
Price
1Y↑ +83.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$450.2M
Enterprise Value
$213.8M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$156.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-80.0%
ROIC
—
Debt / Equity
—
Net Cash
$236.4M
Return 1Y
+83.0%
Company profile
We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. We were incorporated in Delaware in June 2018 under the name BAIT Therapeutics, Inc., and changed our name to Kyverna Therapeutics, Inc. in October 2019. Our principal executive offices are located at 5980 Horton St., STE 550, Emeryville, CA.
- CEO
- Peter Maag
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- kyvernatx.com
Management & directors
- Shaw ChristiExecutive Chairperson
- Biddle Warner WestonChief Executive Officer
- Gehchan NajiSee Remarks
- Grasso MarcChief Financial Officer
- Walker Karen MarieChief Technology Officer
Roles derived from SEC Form 4 filings.
Earnings
KYTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.66↓ -35.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$62.4M | -$142.6M | -$169.8M |
| Net income | -$60.4M | -$127.5M | -$161.3M |
| Diluted EPS | -$89.61 | -$3.33 | -$3.64 |
| Operating cash flow | -$52.4M | -$114.3M | -$153.7M |
| Free cash flow | -$53.0M | -$116.5M | -$153.7M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.4M | -$38.8M | -$41.0M | -$47.4M | -$44.4M | -$38.7M | -$39.3M | -$41.4M |
| Net income | -$28.8M | -$34.5M | -$37.5M | -$44.6M | -$42.1M | -$36.8M | -$37.8M | -$39.7M |
| Diluted EPS | -$0.67 | -$0.80 | -$0.74 | -$1.03 | -$0.97 | -$0.85 | -$0.79 | -$0.66 |
| Operating cash flow | -$24.2M | -$27.5M | -$37.1M | -$44.9M | -$31.9M | -$43.3M | -$33.5M | -$41.6M |
| Free cash flow | -$25.2M | -$27.6M | -$37.6M | -$44.9M | -$32.0M | -$43.3M | -$33.5M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | Shaw Christi· Executive Chairperson | Tax withholding | 4,194 | $8.59 | $36,026.46 | filing |
| 2026-05-27 | Cohen Fred E | Award | 5,093 | $0.00 | $0.00 | filing |
| 2026-05-27 | SEIDENBERG BETH C | Award | 5,093 | $0.00 | $0.00 | filing |
| 2026-05-27 | Aktar Mert | Award | 5,093 | $0.00 | $0.00 | filing |
| 2026-05-27 | CLARK IAN T | Award | 5,093 | $0.00 | $0.00 | filing |
| 2026-03-13 | GEHCHAN NAJI· See Remarks | Award | 18,000 | $0.00 | $0.00 | filing |
| 2026-03-13 | GRASSO MARC· Chief Financial Officer | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-03-13 | Biddle Warner Weston· Chief Executive Officer | Award | 58,000 | $0.00 | $0.00 | filing |
| 2026-02-24 | Miller Andrew Craig | Award | 11,006 | $0.00 | $0.00 | filing |
| 2026-02-24 | Emany Sravan Kumar | Award | 11,006 | $0.00 | $0.00 | filing |
| 2026-01-12 | Shaw Christi· Executive Chairperson | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-01-12 | Shaw Christi· Executive Chairperson | Award | 24,301 | $0.00 | $0.00 | filing |
| 2025-12-18 | SEIDENBERG BETH C | Buy | 133,333 | $7.50 | $999,997.50 | filing |
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | Buy | 133,333 | $7.50 | $999,997.50 | filing |
| 2025-12-15 | Walker Karen Marie· Chief Technology Officer | Sale | 23,998 | $12.20 | $292,775.60 | filing |
| 2025-12-15 | Walker Karen Marie· Chief Technology Officer | Option exercise | 23,998 | $4.83 | $115,910.34 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.